keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/29901488/decrease-in-total-lesion-glycolysis-and-survival-after-yttrium-90-radioembolization-in-poorly-differentiated-hepatocellular-carcinoma-with-portal-vein-tumour-thrombosis
#1
Luca Filippi, Giovan G Di Costanzo, Antonio D'Agostini, Raffaella Tortora, Giuseppe Pelle, Roberto Cianni, Orazio Schillaci, Oreste Bagni
PURPOSE: This study aims to evaluate the prognostic role of the decrease in total lesion glycolysis (TLG) assessed by fluorine-18-fluorodeoxyglucose (F-FDG) PET-computed tomography (CT) 1 month after yttrium-90-radioembolization (Y-RE) in patients affected by hepatocellular carcinoma (HCC) with portal vein tumour thrombosis (PVTT). PATIENTS AND METHODS: Twenty-one patients with histologically proven poorly differentiated HCC and evidence of PVTT at the enhanced multislice CT underwent Y-RE...
June 12, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29887263/intra-arterial-therapies-for-unresectable-and-chemorefractory-colorectal-cancer-liver-metastases-a-systematic-review-and-meta-analysis
#2
REVIEW
Jordan Levy, Jesse Zuckerman, Richard Garfinkle, Sergio A Acuna, Jacynthe Touchette, Tsafrir Vanounou, Jean-Sebastien Pelletier
BACKGROUND: A large proportion of patients with colorectal cancer liver metastases (CRCLM) not amenable to curative liver resection will progress on systemic therapy. Intra-arterial therapies (IAT) including conventional transarterial chemoembolization (cTACE), drug eluting beads (DEB-TACE) and yttrium-90 radioembolization (Y-90) are indicated to prolong survival and palliate symptoms. The purpose of this systematic review and meta-analysis is to compare the survival benefit and radiologic response of three intra-arterial therapies in patients with chemorefractory and unresectable CRCLM...
June 7, 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/29886488/liver-resection-for-colorectal-hepatic-metastases-after-systemic-chemotherapy-and-selective-internal-radiation-therapy-with-yttrium-90-microspheres-a-systematic-review
#3
REVIEW
Minas Baltatzis, Ajith K Siriwardena
BACKGROUND: Selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres has been used together with systemic chemotherapy to treat patients with unresectable liver metastases. This study undertook the first systematic pooled assessment of the case profile, treatment and outcome in patients with initially inoperable colorectal hepatic metastases undergoing resection after systemic chemotherapy and SIRT. METHODS: A systematic review of the literature was performed using Medline and Embase for publications between January 1998 and August 2017...
June 8, 2018: Digestive Surgery
https://www.readbyqxmd.com/read/29849654/a-woman-with-black-beads-in-her-stomach-severe-gastric-ulceration-caused-by-yttrium-90-radioembolization
#4
Indu S Voruganti, James L Godwin, Alyn Adrain, Edward Feller
Radioembolization (RE) is a selective internal radiation therapy (SIRT) delivering targeted, high-dose, intra-arterial radiation directly to the vascular supply of liver tumors. Complications can occur due to aberrant deposition or migration of radiation microspheres into nontarget locations, including normal hepatic parenchyma, lungs, pancreas, and upper gastrointestinal (UGI) tract. We report a case of gastric ulcers due to yttrium-90 (90 Y) seed migration to the stomach to alert clinicians to this rare cause of gastric injury...
2018: Case Reports in Medicine
https://www.readbyqxmd.com/read/29786487/diffusion-weighted-mri-is-superior-to-pet-ct-in-predicting-survival-of-patients-undergoing-90-y-radioembolization-of-hepatic-metastases
#5
Alexandra Barabasch, Alexander Heinzel, Philipp Bruners, Nils A Kraemer, Christiane K Kuhl
Purpose To determine the relationship between diffusion-weighted (DW) liver MR images obtained 4-6 weeks after lobar yttrium 90 (90 Y) treatment and overall survival in comparison with PET/CT or established oncologic factors known to affect survival. Materials and Methods The institutional review board approved this prospective intraindividual comparative study in 36 consecutive patients (25 women) with liver-dominant metastases (20 colorectal, 14 breast, two other) (mean age, 60 years ± 10 [standard deviation]) who underwent fluorine 18 (18 F) fluorodeoxyglucose (FDG) PET/CT and DW MRI before and 4-6 weeks after 90 Y radioembolization...
May 21, 2018: Radiology
https://www.readbyqxmd.com/read/29754852/predictors-of-survival-after-yttrium-90-radioembolization-for-colorectal-cancer-liver-metastases
#6
Ashley A Weiner, Bin Gui, Neil B Newman, John L Nosher, Fady Yousseff, Shou-En Lu, Gretchen M Foltz, Darren Carpizo, Jonathan Lowenthal, Darryl A Zuckerman, Ben Benson, Jeffrey R Olsen, Salma K Jabbour, Parag J Parikh
PURPOSE: To identify clinical parameters that are prognostic for improved overall survival (OS) after yttrium-90 radioembolization (RE) in patients with liver metastases from colorectal cancer (CRC). MATERIALS AND METHODS: A total of 131 patients who underwent RE for liver metastases from CRC, treated at 2 academic centers, were reviewed. Twenty-one baseline pretreatment clinical factors were analyzed in relation to OS by the Kaplan-Meier method along with log-rank tests and univariate and multivariate Cox regression analyses...
May 10, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29753675/patient-radiation-exposure-in-transradial-versus-transfemoral-yttrium-90-radioembolization-a-retrospective-propensity-score-matched-analysis
#7
Joshua Loewenstern, Colton Welch, Safet Lekperic, Vivian Bishay, Mona Ranade, Rahul S Patel, Edward Kim, F Scott Nowakowski, Robert A Lookstein, Aaron M Fischman
PURPOSE: To compare differences in patient radiation exposure (PRE) during transarterial yttrium-90 (90 Y) radioembolization (TARE) between transradial access (TRA) and transfemoral access (TFA). MATERIALS AND METHODS: A total of 810 consecutive first-time TARE procedures in patients from 2013 to 2017 were retrospectively reviewed. A propensity score-matching (PSM) analysis matched TRA and TFA groups on the basis of patient age, sex, weight, height, cancer type, 90 Y microsphere type, and number of previous procedures from the same and opposite approaches...
May 9, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29737954/-90-y-radioembolization-for-hepatic-malignancy-in-patients-with-previous-biliary-intervention-multicenter-analysis-of-hepatobiliary-infections
#8
Kavi K Devulapalli, Nicholas Fidelman, Michael C Soulen, Matthew Miller, Matthew S Johnson, Eric Addo, Ghassan El-Haddad, Charles Nutting, James Morrison, Khashayar Farsad, R Peter Lokken, Ron C Gaba, Jacob Fleming, Daniel B Brown, Sharon W Kwan, Steven C Rose, Kevin A Pennycooke, David M Liu, Sarah B White, Ripal Gandhi, Ann A Lazar, Robert K Kerlan
Purpose To determine the frequency of hepatobiliary infections after transarterial radioembolization (TARE) with yttrium 90 (90 Y) in patients with liver malignancy and a history of biliary intervention. Materials and Methods For this retrospective study, records of all consecutive patients with liver malignancy and history of biliary intervention treated with TARE at 14 centers between 2005 and 2015 were reviewed. Data regarding liver function, 90 Y dosimetry, antibiotic prophylaxis, and bowel preparation prophylaxis were collected...
May 8, 2018: Radiology
https://www.readbyqxmd.com/read/29733658/bevacizumab-radioimmunotherapy-rit-with-accelerated-blood-clearance-using-the-avidin-chase
#9
Ryan Yudistiro, Hirofumi Hanaoka, Natsumi Katsumata, Aiko Yamaguchi, Yoshito Tsushima
The overexpression of vascular endothelial growth factor (VEGF) in varying types of solid tumor renders radioimmunotherapy (RIT) with the anti-VEGF antibody bevacizumab (BV) a promising treatment. However, the slow blood clearance of BV, which may increase the occurrence risk of hematotoxicity, hinders the application of BV-RIT. Using the avidin chase is a long-known blood clearance enhancement strategy for biotinylated-mAb. To enhance RIT efficacy by increasing the radioactivity dose, we evaluated the ability of avidin to accelerate the blood clearance of yttrium-90 (90 Y)-labeled biotinylated BV (90 Y-Bt-BV) in a xenograft mouse model of triple-negative breast cancer (TNBC)...
May 7, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29724520/long-term-toxicity-after-transarterial-radioembolization-with-yttrium-90-using-resin-microspheres-for-neuroendocrine-tumor-liver-metastases
#10
Yuki Tomozawa, Younes Jahangiri, Priya Pathak, Kenneth J Kolbeck, Ryan C Schenning, John A Kaufman, Khashayar Farsad
PURPOSE: To evaluate long-term effects of yttrium-90 (90 Y) transarterial radioembolization (TARE) for unresectable hepatic metastases of neuroendocrine tumors (NETs). MATERIALS AND METHODS: Retrospective analysis of 93 patients (47 women, 46 men; mean age 59 y) who underwent resin-based 90 Y TARE was performed. Variables associated with overall survival were analyzed using univariate and multivariate models. Changes in serologic values and imaging characteristics were assessed with long-term follow-up...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29724518/response-and-overall-survival-for-yttrium-90-radioembolization-of-hepatic-sarcoma-a-multicenter-retrospective-study
#11
Matthew D Miller, Daniel Y Sze, Siddharth A Padia, Robert J Lewandowski, Riad Salem, Philani Mpofu, Paul M Haste, Matthew S Johnson
PURPOSE: To evaluate the effectiveness and safety of yttrium-90 transarterial radioembolization (TARE) for the treatment of primary and metastatic soft tissue sarcoma (STS) of the liver. MATERIALS AND METHODS: A retrospective review of 39 patients with primary (n = 2) and metastatic (n = 37) hepatic STS treated with TARE at 4 institutions was performed. Fourteen STS subtypes were included, with leiomyosarcoma being the most common (51%). TARE with glass (22 patients) or resin (17 patients) microspheres was performed, with single lobe (17 patients) or bilobar treatment (22 patients) based on disease burden...
April 30, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29709062/management-of-newly-diagnosed-high-risk-and-intermediate-risk-follicular-lymphoma-with-90-y-ibritumomab-tiuxetan-in-a-phase-ii-study
#12
Neil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, Rena Buckstein, Eugenia Piliotis, Kevin R Imrie, Lisa Chodirker, Mary-Anne Cussen, Ellen Miles, Marciano D Reis, Zeina Ghorab, Matthew C Cheung
Five-year overall survival for high-risk Follicular Lymphoma International Prognostic Index follicular lymphoma is only approximately 50% compared with 90% for low risk. To evaluate an approach to improve upon this poor outcome, we completed an exploratory phase II trial of intensified treatment for patients with intermediate and high-risk follicular lymphoma. Front-line treatment with chemo-immunotherapy consisting of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone was followed by radio- immunotherapy with 90-Yttrium ibritumomab tiuxetan consolidation, and 2 years of rituximab maintenance...
April 30, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29705239/reply-to-validation-of-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#13
LETTER
Carlo Sposito, Carlo Spreafico, Vincenzo Mazzaferro
No abstract text is available yet for this article.
July 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29683787/selective-internal-radiation-therapy-sirt-as-treatment-for-hepatic-metastases-of-uveal-melanoma-a-finnish-nation-wide-retrospective-experience
#14
Sanni Tulokas, Hanna Mäenpää, Erno Peltola, Tero Kivelä, Pia Vihinen, Aku Virta, Siru Mäkelä, Raija Kallio, Micaela Hernberg
BACKGROUND: In Finland, selective internal radiation therapy (SIRT) is at present the preferred first-line loco-regional therapy for uveal melanoma patients with hepatic metastases not suitable for surgery. We retrospectively evaluate the outcome and safety of SIRT in this group of patients. MATERIAL AND METHODS: Yttrium-90 microspheres were delivered via the hepatic artery into the circulation of metastases from uveal melanoma in 18 patients with a predicted life expectancy of more than three months in three Finnish tertiary referral centers between November 2010 and December 2015...
April 23, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29682195/results-and-adverse-events-of-personalized-peptide-receptor-radionuclide-therapy-with-90-yttrium-and-177-lutetium-in-1048-patients-with-neuroendocrine-neoplasms
#15
Richard P Baum, Harshad R Kulkarni, Aviral Singh, Daniel Kaemmerer, Dirk Mueller, Vikas Prasad, Merten Hommann, Franz C Robiller, Karin Niepsch, Holger Franz, Arthur Jochems, Philippe Lambin, Dieter Hörsch
Introduction: Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study. Methods: In our center, 2294 patients were screened between 2004 and 2014 by 68 Ga somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 1048 patients, who received at least one cycle of 90 Yttrium or 177 Lutetium-based PRRT...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29663029/yttrium-90-ibritumomab-tiuxetan-zevalin-followed-by-beam-z-beam-conditioning-regimen-and-autologous-stem-cell-transplantation-asct-in-relapsed-or-refractory-high-risk-b-cell-non-hodgkin-lymphoma-nhl-a-single-institution-italian-experience
#16
Chiara Ciochetto, Barbara Botto, Roberto Passera, Marilena Bellò, Giulia Benevolo, Carola Boccomini, Alessia Castellino, Annalisa Chiappella, Roberto Freilone, Maura Nicolosi, Lorella Orsucci, Clara Pecoraro, Patrizia Pregno, Gianni Bisi, Umberto Vitolo
Chemo-refractory NHL has a very poor outcome; the addiction of RIT to salvage regiment pre ASCT had recently demonstrated promising results.We performed a retrospective sequential study to determine the feasibility of standard Zevalin with BEAM in high-risk relapse/refractory NHL. A matched cohort analysis with a group treated with standard BEAM without Zevalin was performed as secondary endpoint. Between October 2006 and January 2013, 37 NHL patients at high risk for progression or early (< 1 year) or multiple relapses were treated with Z-BEAM and ASCT after R-DHAP or R-ICE as salvage therapy...
April 16, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29651580/hepatotoxic-dose-thresholds-by-positron-emission-tomography-after-yttrium-90-radioembolization-of-liver-tumors-a-prospective-single-arm-observational-study
#17
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To define a threshold radiation dose to non-tumoral liver from 90 Y radioembolization that results in hepatic toxicity using pair-production PET. MATERIALS AND METHODS: This prospective single-arm study enrolled 35 patients undergoing radioembolization. A total of 34 patients (27 with HCC and 7 with liver metastases) were included in the final analysis. Of 27 patients with underlying cirrhosis, 22 and 5 patients were Child-Pugh A and B, respectively. Glass and resin microspheres were used in 32 (94%) and 2 (6%) patients, respectively...
April 12, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29616365/multi-institutional-quantitative-phantom-study-of-yttrium-90-pet-in-pet-mri-the-mr-quest-study
#18
Nichole M Maughan, Mootaz Eldib, David Faul, Maurizio Conti, Mattijs Elschot, Karin Knešaurek, Francesca Leek, David Townsend, Frank P DiFilippo, Kimberly Jackson, Stephan G Nekolla, Mathias Lukas, Michael Tapner, Parag J Parikh, Richard Laforest
BACKGROUND: Yttrium-90 (90 Y) radioembolization involves the intra-arterial delivery of radioactive microspheres to treat hepatic malignancies. Though this therapy involves careful pre-treatment planning and imaging, little is known about the precise location of the microspheres once they are administered. Recently, there has been growing interest post-radioembolization imaging using positron-emission tomography (PET) for quantitative dosimetry and identifying lesions that may benefit from additional salvage therapy...
April 4, 2018: EJNMMI Physics
https://www.readbyqxmd.com/read/29578364/treatment-of-hepatocellular-carcinoma-a-cost-analysis-of-yttrium-90-transarterial-radioembolization-versus-sorafenib
#19
Maria Grazia Lucà, Roberto Nani, Melanie Schranz, Massimo De Giorgio, Claudia Iegri, Roberto Agazzi, Francesco Sala, Giorgio Virotta, Donatella Sarti, Grazia Conte, Domenico Pinelli, Carlo Nicora, Michele Colledan, Sandro Sironi, Stefano Fagiuoli
AIM: The aim was to evaluate cost-effectiveness of yttrium-90 transarterial radioembolization (TARE) in comparison to sorafenib treatment. PATIENTS & METHODS: A single-center, retrospective, observational study was performed, 166 patients with intermediate-/advanced-stage hepatocellular carcinoma were treated with sorafenib and 19 with TARE. The patients out of the sorafenib group matching the inclusion criteria for TARE, were reassigned to a subgroup SOR3...
April 2018: Future Oncology
https://www.readbyqxmd.com/read/29559288/prospective-trial-using-internal-pair-production-positron-emission-tomography-to-establish-the-yttrium-90-radioembolization-dose-required-for-response-of-hepatocellular-carcinoma
#20
Keith T Chan, Adam M Alessio, Guy E Johnson, Sandeep Vaidya, Sharon W Kwan, Wayne Monsky, Ann E Wilson, David H Lewis, Siddharth A Padia
PURPOSE: To prospectively assess the threshold dose for objective response of hepatocellular carcinoma (HCC), using 90 Y internal pair-production positron emission tomography (PET) to quantify the radiation dose delivered to hepatic tumors after radioembolization. METHODS AND MATERIALS: A prospective study was performed under institutional review board approval from 2012 to 2014. Thirty-five patients with primary and secondary liver tumors undergoing 90 Y treatment were recruited...
June 1, 2018: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"